Gene: ND6

4541
MTND6
NADH dehydrogenase, subunit 6 (complex I)
protein-coding
-
Ensembl:ENSG00000198695 MIM:516006 UniprotKB:P03923
NC_011137.1
PubMed
0   ANCO-SNPs
ND|AD
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
NA (AD)  NA (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00157NADHSmall Molecule58-68-4Approved|NutraceuticalTarget
ID Drug Name Action PubMed
C0447551-methyl-4-phenyl-2,3-dihydropyridinium"1-methyl-4-phenyl-2,3-dihydropyridinium results in decreased expression of ND6 mRNA"21856379
C5495433-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid analog results in increased expression of ND6 mRNA25716159
C517041(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)"(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II) results in decreased expression of ND6 mRNA"19561079
C027696acipimoxacipimox results in decreased expression of ND6 mRNA25352640
C005948astaxanthineastaxanthine inhibits the reaction [LEPR gene mutant form results in increased expression of ND6 mRNA]16964424
D001280AtrazineAtrazine results in decreased expression of ND6 mRNA22378314|2711463
D001280AtrazineAtrazine results in increased expression of ND6 mRNA26518232
D001280AtrazineAtrazine results in increased expression of ND6 mRNA27114639
C030935benz(a)anthracenebenz(a)anthracene results in decreased expression of ND6 mRNA26377693
C030935benz(a)anthracene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA27858113
C006703benzo(b)fluoranthene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA27858113
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of ND6 mRNA26377693
C022921benzo(k)fluoranthenebenzo(k)fluoranthene results in decreased expression of ND6 mRNA26377693
D001564Benzo(a)pyrene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA27858113
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of ND6 mRNA27195522
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of ND6 mRNA"20382639
C543008bis(4-hydroxyphenyl)sulfone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ND6 mRNA28628672
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ND6 mRNA28628672
C006780bisphenol Abisphenol A results in decreased expression of ND6 mRNA25181051
D002235Carbofuran[Lindane co-treated with metolachlor co-treated with Carbofuran] results in decreased expression of ND6 mRNA21075942
D002331CarnitineCarnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA]21419151
C031180chrysene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA27858113
C073341citraconic acidcitraconic acid results in increased expression of ND6 mRNA27277809
C073341citraconic acidNFE2L2 protein affects the reaction [citraconic acid results in increased expression of ND6 mRNA]27277809
D019327Copper SulfateCopper Sulfate results in increased expression of ND6 mRNA19549813
C057862cyanoginosin LRcyanoginosin LR results in increased expression of ND6 mRNA23342045
D003703DemecolcineDemecolcine results in increased expression of ND6 mRNA23649840
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ND6 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ND6 mRNA28628672
D016264Dextran SulfateDextran Sulfate results in increased expression of ND6 mRNA23894361
D004317DoxorubicinND6 gene mutant form results in decreased susceptibility to Doxorubicin15248896
D004317DoxorubicinDoxorubicin results in decreased expression of ND6 mRNA28865727
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ND6 mRNA22079256
D005485FlutamideFlutamide results in decreased expression of ND6 mRNA19442681
D005557FormaldehydeFormaldehyde results in increased expression of ND6 mRNA23649840
D005690GalactoseND6 protein affects the metabolism of Galactose9707444
C001277geldanamycingeldanamycin results in increased expression of ND6 mRNA26705709
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ND6 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ND6 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ND6 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ND6 mRNA28628672
C410337K 7174K 7174 results in increased expression of ND6 mRNA24086573
D001556Lindane[Lindane co-treated with metolachlor co-treated with Carbofuran] results in decreased expression of ND6 mRNA21075942
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of ND6 mRNA28001369
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in decreased expression of ND6 mRNA24810058|2610203
D0156551-Methyl-4-phenylpyridiniumMTERF4 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of ND6 mRNA]26102036
C051786metolachlor[Lindane co-treated with metolachlor co-treated with Carbofuran] results in decreased expression of ND6 mRNA21075942
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of ND6 mRNA"25554681|2562005
C022838nickel chlorideCarnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA]21419151
C022838nickel chloridenickel chloride results in decreased expression of ND6 mRNA21419151
D010100OxygenND6 gene mutant form affects the susceptibility to Oxygen deficiency15248896
C023036perfluorooctanoic acidperfluorooctanoic acid results in increased expression of ND6 mRNA28511854
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ND6 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of ND6 mRNA22079256
D012402RotenoneND6 gene mutant form results in decreased susceptibility to Rotenone15248896
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of ND6 mRNA25895662
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of ND6 mRNA15716485
D019284ThapsigarginThapsigargin results in decreased expression of ND6 mRNA22378314
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of ND6 mRNA"26179874
D014415TunicamycinTunicamycin results in decreased expression of ND6 mRNA22378314
D014520UrethaneUrethane results in increased expression of ND6 mRNA28818685
D014750VincristineVincristine results in increased expression of ND6 mRNA23649840
D014874Water Pollutants, Chemical"Water Pollutants, Chemical results in increased expression of ND6 mRNA"25475078

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0008137NADH dehydrogenase (ubiquinone) activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0032981mitochondrial respiratory chain complex I assembly-TAS-  
GO:0035094response to nicotine-IEA-  
GO:0042220response to cocaine-IEA-  
GO:0042542response to hydrogen peroxide-IEA-  
GO:0055114oxidation-reduction process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005743mitochondrial inner membrane-TAS-  
GO:0016021integral component of membrane-IEA-  
GO:0070469respiratory chain-IEA-  
KEGG ID KEGG Term
hsa00190Oxidative phosphorylation
hsa01100Metabolic pathways
hsa05012Parkinson's disease
Reactome ID Reactome Term Evidence
R-HSA-1428517The citric acid (TCA) cycle and respiratory electron transportTAS
R-HSA-1430728MetabolismTAS
R-HSA-163200Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.TAS
R-HSA-611105Respiratory electron transportTAS
R-HSA-6799198Complex I biogenesisTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
19494790Polymorphisms in mitochondrial genes encoding complex I subunits are maternal factors of voluntary alcohol consumption in the rat. (2009 Jul)Sapag APharmacogenet Genomics
28630220Beyond cervical lipomas: myoclonus, gait disorder and multisystem involvement leading to mitochondrial disease. (2017 Jun 19)Lopez-Blanco RBMJ Case Rep